FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311005008> ?p ?o ?g. }

• W4311005008 endingPage "154594" @default.
• W4311005008 startingPage "154594" @default.
• W4311005008 abstract "Over-activation of N-methyl-D-aspartate receptors (NMDARs) is involved in sporadic Alzheimer's disease. Silibinin, a natural flavonoid gained from the seeds of Silybum marianum, exerts neuroprotective effects on sporadic AD models, but its impacts on NMDARs remain unknown.To study silibinin's regulatory effects on NMDARs pathway in sporadic AD models.MTT assay, western blotting, confocal microscopy, flow cytometry, RT-PCR, and siRNA transfection etc. were used for cellular and molecular studies. The direct interactions between silibinin and NMDAR subunits were evaluated by computational molecular docking, drug affinity responsive target stability (DARTS) assay and cellular thermal shift assay (CETSA). Y maze test, novel objects recognition test and Morris water maze test were conducted to examine the learning and memory ability of rats.An in vitro AD model was established by treating HT22 murine hippocampal neurons with streptozotocin (STZ), as evidenced by the amyloid β (Aβ) deposition and hyperphosphorylation of tau proteins. Silibinin shows protection of neurons against STZ-induced cell damage. It is noteworthy that STZ-induced cellular calcium influx is inhibited by silibinin-treatment, indicating the possible modulation of calcium channels. Studies on NMDARs, the most widely distributed calcium channel, by using molecular docking, DARTS and CESTA, reveal that the GluN2B subunit, but not GluN2A, is the potential target of silibinin. Further studies using the pharmacological agonist (NMDA) and the GluN2B-specific inhibitor (Ifenprodil) or siRNA, indicate that the protection by silibinin treatment from STZ-induced cytotoxicity is medicated through interference with GluN2B-containing NMDARs, followed by the upregulation of CaMKIIα/ BDNF/ TrkB signaling pathway and improved levels of synaptic proteins (SYP and PSD-95). The results in vivo using rats intracerebroventricularly injected with STZ (ICV-STZ), a well-established sporadic AD model, confirm that silibinin improves learning and memory ability in association with modulation of the GluN2B/CaMKIIα/ BDNF/TrkB signaling pathway.Inhibiting over-activation of GluN2B-containing NMDARs is involved in the neuroprotective effect of silibinin on STZ-induced sporadic AD models." @default.
• W4311005008 created "2022-12-22" @default.
• W4311005008 creator A5011855770 @default.
• W4311005008 creator A5026283201 @default.
• W4311005008 creator A5034644025 @default.
• W4311005008 creator A5038190695 @default.
• W4311005008 creator A5039779230 @default.
• W4311005008 creator A5045272575 @default.
• W4311005008 creator A5051429814 @default.
• W4311005008 creator A5054986891 @default.
• W4311005008 creator A5066953191 @default.
• W4311005008 creator A5069771785 @default.
• W4311005008 creator A5079036030 @default.
• W4311005008 date "2023-01-01" @default.
• W4311005008 modified "2023-09-28" @default.
• W4311005008 title "Inhibition of GluN2B pathway is involved in the neuroprotective effect of silibinin on streptozotocin-induced Alzheimer's disease models" @default.
• W4311005008 cites W1993441295 @default.
• W4311005008 cites W2507955795 @default.
• W4311005008 cites W2562311440 @default.
• W4311005008 cites W2757392195 @default.
• W4311005008 cites W2768179257 @default.
• W4311005008 cites W2770618300 @default.
• W4311005008 cites W2788640168 @default.
• W4311005008 cites W2791002606 @default.
• W4311005008 cites W2799968925 @default.
• W4311005008 cites W2885888452 @default.
• W4311005008 cites W2893001433 @default.
• W4311005008 cites W2900979298 @default.
• W4311005008 cites W2901147556 @default.
• W4311005008 cites W2913192471 @default.
• W4311005008 cites W2940748493 @default.
• W4311005008 cites W2943665263 @default.
• W4311005008 cites W2952413884 @default.
• W4311005008 cites W2981768716 @default.
• W4311005008 cites W3001459179 @default.
• W4311005008 cites W3012828832 @default.
• W4311005008 cites W3037752736 @default.
• W4311005008 cites W3045461893 @default.
• W4311005008 cites W3046971542 @default.
• W4311005008 cites W3091350622 @default.
• W4311005008 cites W3092218098 @default.
• W4311005008 cites W3095448378 @default.
• W4311005008 cites W3109464361 @default.
• W4311005008 cites W3127367560 @default.
• W4311005008 cites W3163917991 @default.
• W4311005008 cites W3181730654 @default.
• W4311005008 cites W3197439249 @default.
• W4311005008 cites W3204305905 @default.
• W4311005008 cites W3213215676 @default.
• W4311005008 cites W4200230151 @default.
• W4311005008 cites W4206774749 @default.
• W4311005008 cites W4220995427 @default.
• W4311005008 cites W4221091185 @default.
• W4311005008 cites W4235875658 @default.
• W4311005008 cites W4284978145 @default.
• W4311005008 cites W4289519281 @default.
• W4311005008 cites W4292566989 @default.
• W4311005008 cites W4294151542 @default.
• W4311005008 cites W4306399136 @default.
• W4311005008 cites W4306920593 @default.
• W4311005008 doi "https://doi.org/10.1016/j.phymed.2022.154594" @default.
• W4311005008 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36610115" @default.
• W4311005008 hasPublicationYear "2023" @default.
• W4311005008 type Work @default.
• W4311005008 citedByCount "2" @default.
• W4311005008 countsByYear W43110050082023 @default.
• W4311005008 crossrefType "journal-article" @default.
• W4311005008 hasAuthorship W4311005008A5011855770 @default.
• W4311005008 hasAuthorship W4311005008A5026283201 @default.
• W4311005008 hasAuthorship W4311005008A5034644025 @default.
• W4311005008 hasAuthorship W4311005008A5038190695 @default.
• W4311005008 hasAuthorship W4311005008A5039779230 @default.
• W4311005008 hasAuthorship W4311005008A5045272575 @default.
• W4311005008 hasAuthorship W4311005008A5051429814 @default.
• W4311005008 hasAuthorship W4311005008A5054986891 @default.
• W4311005008 hasAuthorship W4311005008A5066953191 @default.
• W4311005008 hasAuthorship W4311005008A5069771785 @default.
• W4311005008 hasAuthorship W4311005008A5079036030 @default.
• W4311005008 hasConcept C134018914 @default.
• W4311005008 hasConcept C170493617 @default.
• W4311005008 hasConcept C185592680 @default.
• W4311005008 hasConcept C25498285 @default.
• W4311005008 hasConcept C2777130413 @default.
• W4311005008 hasConcept C2779280383 @default.
• W4311005008 hasConcept C2780376555 @default.
• W4311005008 hasConcept C55493867 @default.
• W4311005008 hasConcept C555293320 @default.
• W4311005008 hasConcept C67018056 @default.
• W4311005008 hasConcept C86803240 @default.
• W4311005008 hasConcept C98274493 @default.
• W4311005008 hasConceptScore W4311005008C134018914 @default.
• W4311005008 hasConceptScore W4311005008C170493617 @default.
• W4311005008 hasConceptScore W4311005008C185592680 @default.
• W4311005008 hasConceptScore W4311005008C25498285 @default.
• W4311005008 hasConceptScore W4311005008C2777130413 @default.
• W4311005008 hasConceptScore W4311005008C2779280383 @default.
• W4311005008 hasConceptScore W4311005008C2780376555 @default.
• W4311005008 hasConceptScore W4311005008C55493867 @default.

• next